Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on April 21, 2005

Arteriosclerosis, Thrombosis, and Vascular Biology. 2005
Published online before print April 21, 2005, doi: 10.1161/01.ATV.0000166602.04711.2e
A more recent version of this article appeared on July 1, 2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/7/1489    most recent
01.ATV.0000166602.04711.2ev1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Almasy, L.
Right arrow Articles by Blangero, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almasy, L.
Right arrow Articles by Blangero, J.

Submitted on February 8, 2005
Accepted on April 7, 2005

A Locus on Chromosome 2 Influences Levels of Tissue Factor Pathway Inhibitor. Results From the GAIT study

L. Almasy *; J. M. Soria ; J. C. Souto ; D. M. Warren ; A. Buil ; M. Borrell ; X. Muñoz ; N. Sala ; M. Lathrop ; J. Fontcuberta ; and J. Blangero

From the Southwest Foundation for Biomedical Research (L.A., D.M.W, J.B.), San Antonio, Tex; the Hospital de la Santa Creu i Sant Pau (J.M.S., J.C.S., A.B., J.F.), Barcelona, Spain; the Institut de Recerca Oncologica (X.M., N.S.), Barcelona, Spain; and the Centre National de Genotypage (M.L.), Evry, France.

* To whom correspondence should be addressed. E-mail: almasy{at}darwin.sfbr.org.

Objective--Levels of tissue factor pathway inhibitor (TFPI) have been associated with arteriosclerosis and thrombotic disease. Although a genetic component to variation in TFPI levels is well-documented, no systematic genome-wide screens have been conducted to localize genes influencing levels of TFPI.

Methods and Results--We studied TFPI levels in 397 individuals in 21 Spanish families participating in the Genetic Analysis of Idiopathic Thrombosis (GAIT) study. Twelve families were selected through a proband with idiopathic thrombosis and 9 were ascertained without regard to phenotype. A genome scan was performed using microsatellite markers spaced at approximately 10 cM intervals. Standard multipoint variance component linkage methods were used. The heritability of TFPI levels was 0.52 (P<0.0001), with no evidence for shared household effects. In the genome screen, only 1 LOD score >2 was observed. On chromosome 2q, the maximum multipoint LOD score was 3.52 near marker D2S1384. This is near the structural gene for TFPI, which is located at 2q32. In follow-up association analyses, marginal evidence of association (P=0.04) was observed with the TFPI promoter variant C-399T.

Conclusion--These results suggest that polymorphisms in and around the TFPI structural gene may be the major genetic determinants of variation in TFPI levels.


Key words: TFPI • linkage • association • heritability